Fluorizoline
目录号 : GC62167
Fluorizoline 选择性地直接结合到 prohibitin 1 (PHB1) 和 2 (PHB2),并诱导凋亡。Fluorizoline 通过上调 NOXA 和 BIM 降低慢性淋巴细胞性白血病 (CLL) 细胞的活力。Fluorizoline 以 p53 非依赖性方式发挥抗肿瘤作用。
Cas No.:1362243-70-6
Sample solution is provided at 25 µL, 10mM.
Fluorizoline selectively and directly binds to prohibitin 1 (PHB1) and 2 (PHB2), and induces apoptosis. Fluorizoline reduces chronic lymphocytic leukemia (CLL) cell viability through the upregulation of NOXA and BIM. Fluorizoline exerts antitumor action in a p53-independent manner[1].
Fluorizoline (1.25-20 μM; 24 hours) induces apoptosis in primary CLL cells ex vivo[1]. Fluorizoline (5-10 μM; 48 hours) causes an increase of NOXA protein levels[1]. Fluorizoline reduces the percentage of viable normal B and T cells (48.6% and 82.8% of viable cells at 24 hours of treatment with 10 μM Fluorizoline in normal CD19+ and CD3+ populations, respectively) with mean EC50 values of 10.9 μM and 19.1 μM at 24 hours for normal B and T cells, respectively[1].
Fluorizoline (15 mg/kg; ip; three times a week for five weeks) becomes very rapidly (3 weeks) leukemic, as reflected by the increase in the percentage and the number of CD5+CD19+ CLL cells in the blood in 6-week-old recipient C57BL/6 Eμ-TCL1 mouse model of CLL. Fluorizoline does not induce apoptosis in vivo. Fluorizoline does not control disease development in the spleen as indicated by enlarged spleens[2].
[1]. Ana M Cosialls, et al. The prohibitin-binding compound fluorizoline induces apoptosis in chronic lymphocytic leukemia cells through the upregulation of NOXA and synergizes with ibrutinib, 5-aminoimidazole-4-carboxamide riboside or venetoclax. Haematologica. 2017 Sep;102(9):1587-1593.
[2]. Marina Wierz, et al. The prohibitin-binding compound fluorizoline induces apoptosis in chronic lymphocytic leukemia cells ex vivo but fails to prevent leukemia development in a murine model. Haematologica. 2018 Apr;103(4):e154-e157.
Cas No. | 1362243-70-6 | SDF | |
分子式 | C15H8Cl2F3NS | 分子量 | 362.2 |
溶解度 | DMSO : 50 mg/mL (138.05 mM; Need ultrasonic) | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
![]() |
1 mg | 5 mg | 10 mg |
1 mM | 2.7609 mL | 13.8045 mL | 27.6091 mL |
5 mM | 0.5522 mL | 2.7609 mL | 5.5218 mL |
10 mM | 0.2761 mL | 1.3805 mL | 2.7609 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet